Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

**Investment Thesis:** January's top-yielding Aristocrats include Franklin Resources, Realty Income, Amcor, Kenvue, and Hormel, offering dividends from $1K investments exceeding single share prices. *...

As the calendar turns over to 2025, the leading Wall Street firms are releasing their top stock picks for the new year.

Investors worried about a stock market sell-off may feel the urge to sell out of their positions and run for the exits. But long-term investors know that it's a mistake to overhaul your investing stra...

Even with the recent bout of market volatility, 2024 has been a fantastic year for stocks. The S&P 500 index has delivered a dividend-adjusted total return of roughly 25% across this year's trading.

"A Dividend King [is] a stock with 50 or more consecutive years of dividend increases." - suredividend.com. 53 Divided Kings, screened as of December 11, 2024, represented all eleven Morningstar Secto...

"Dividend Aristocrats

Investors often gravitate toward super safe dividend stocks to collect passive income and limit market volatility. But sometimes, even stodgy, boring companies can crush the market.

Kenvue's recent earnings showed improvements, but persistent headwinds, especially in the Skin, Health, & Beauty segment, suggest limited upside potential in the near term. Despite solid dividend grow...

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company's participation in the Morgan Stanley Global Consumer & Retail Conference in New York City. Thibaut Mon...

Kenvue Inc (NYSE:KVUE), the maker of Listerine, Tylenol, Aveeno and Band-Aid, reported slightly lower sales than expected but earnings were just above Wall Street estimates. The company has been in a ...

Kenvue, Inc. (NYSE:KVUE ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Sofya Tsinis - Head, IR Thibaut Mongon - CEO Paul Ruh - CFO Conference Call Participants Bon...

Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Stre...

Kenvue (KVUE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago.

Kenvue reported third-quarter sales marginally below Wall Street estimates on Thursday, hurt by weakness in its skin health and beauty unit housing the Neutrogena and Aveeno brands, amid pressure from...

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal third quarter ended September 29, 2024.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Kenvue (KVUE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua...

Can tinkering around the edges actually make this stock more attractive?

While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.

Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.